{
    "info": {
        "nct_id": "NCT06026371",
        "official_title": "Fecal Microbiota Transplantation to Prevent Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation",
        "inclusion_criteria": "* Age >= 18\n* Signed informed consent\n* Able to take oral medications\n* Planned T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed\n* Planned GVHD prophylaxis using one of the following regimens:\n\n  * Calcineurin inhibitor (tacrolimus or cyclosporine) plus methotrexate\n  * Calcineurin inhibitor (tacrolimus or cyclosporine) plus mycophenolate mofetil (MMF)\n  * Sirolimus plus cyclosporine plus MMF\n  * Post-transplant cyclophosphamide plus calcineurin inhibitor (with or without MMF or sirolimus)\n* One of the following HCT donor types:\n\n  * Human leukocyte antigen (HLA)-matched sibling donor\n  * 9/10 or 10/10 HLA-matched unrelated donor\n  * HLA- haploidentical donor\n  * Cord blood\n* Willing to use at least 1 accepted method of contraception until day 180 after transplant and agree to not donate eggs/sperm for 180 days after\n* Not pregnant or breast feeding\n* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Absolute neutrophil count (ANC) recovery to > 0.5 x 10^9/L from nadir, without ongoing growth factor support\n* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Discontinuation of all antibacterial antibiotics (except those used for Pneumocystis jiroveci prophylaxis) for 2 days\n* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Resolution of all acute toxicities (other than anemia and thrombocytopenia) to Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or lower\n* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Ability to swallow capsules\n* ELIGIBILITY CRITERIA FOR RANDOMIZATION: No grade II-IV acute GVHD\n* ELIGIBILITY CRITERIA FOR RANDOMIZATION: No moderate to severe chronic GVHD\n* ELIGIBILITY CRITERIA FOR RANDOMIZATION: No concurrent antibiotics to treat infections. Prophylactic antiviral and antifungal antibiotics used to prevent infections are allowed\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Severe food allergy in the form of anaphylaxis or attributable symptoms requiring hospitalization\n* History of chronic aspiration or conditions predisposing to aspiration (e.g. neuromuscular disorders)\n* Receiving or planned to receive other experimental agents (including ex vivo T-cell depletion) to prevent GVHD. The use of other experimental agents is prohibited unless approved by the principal investigator (PI) of the other trial",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Ability to swallow capsules",
            "criterions": [
                {
                    "exact_snippets": "Ability to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Post-transplant cyclophosphamide plus calcineurin inhibitor (with or without MMF or sirolimus)",
            "criterions": [
                {
                    "exact_snippets": "Post-transplant cyclophosphamide",
                    "criterion": "post-transplant cyclophosphamide",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "calcineurin inhibitor",
                    "criterion": "calcineurin inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without MMF",
                    "criterion": "MMF (mycophenolate mofetil)",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "optional"
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without ... sirolimus",
                    "criterion": "sirolimus",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "optional"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ELIGIBILITY CRITERIA FOR RANDOMIZATION: No grade II-IV acute GVHD",
            "criterions": [
                {
                    "exact_snippets": "No grade II-IV acute GVHD",
                    "criterion": "acute GVHD",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2,
                                        "unit": "grade"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HLA- haploidentical donor",
            "criterions": [
                {
                    "exact_snippets": "HLA- haploidentical donor",
                    "criterion": "donor HLA matching",
                    "requirements": [
                        {
                            "requirement_type": "HLA match type",
                            "expected_value": "haploidentical"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 9/10 or 10/10 HLA-matched unrelated donor",
            "criterions": [
                {
                    "exact_snippets": "9/10 or 10/10 HLA-matched unrelated donor",
                    "criterion": "HLA match with unrelated donor",
                    "requirements": [
                        {
                            "requirement_type": "match level",
                            "expected_value": [
                                "9/10",
                                "10/10"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sirolimus plus cyclosporine plus MMF",
            "criterions": [
                {
                    "exact_snippets": "Sirolimus",
                    "criterion": "sirolimus",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cyclosporine",
                    "criterion": "cyclosporine",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "MMF",
                    "criterion": "mycophenolate mofetil (MMF)",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to use at least 1 accepted method of contraception until day 180 after transplant and agree to not donate eggs/sperm for 180 days after",
            "criterions": [
                {
                    "exact_snippets": "Willing to use at least 1 accepted method of contraception until day 180 after transplant",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "accepted method"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 180,
                                "unit": "days after transplant"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to not donate eggs/sperm for 180 days after",
                    "criterion": "donation of eggs/sperm",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 180,
                                "unit": "days after transplant"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not pregnant or breast feeding",
            "criterions": [
                {
                    "exact_snippets": "Not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Not ... breast feeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* One of the following HCT donor types:",
            "criterions": [
                {
                    "exact_snippets": "One of the following HCT donor types",
                    "criterion": "HCT donor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "one of the following (list not provided in this line)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed",
            "criterions": [
                {
                    "exact_snippets": "Planned T-replete allogeneic hematopoietic cell transplantation for any indication",
                    "criterion": "planned T-replete allogeneic hematopoietic cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "T-replete allogeneic hematopoietic cell transplantation"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of prior transplantation is allowed",
                    "criterion": "history of prior transplantation",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calcineurin inhibitor (tacrolimus or cyclosporine) plus mycophenolate mofetil (MMF)",
            "criterions": [
                {
                    "exact_snippets": "Calcineurin inhibitor (tacrolimus or cyclosporine)",
                    "criterion": "calcineurin inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug options",
                            "expected_value": [
                                "tacrolimus",
                                "cyclosporine"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "mycophenolate mofetil (MMF)",
                    "criterion": "mycophenolate mofetil use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Discontinuation of all antibacterial antibiotics (except those used for Pneumocystis jiroveci prophylaxis) for 2 days",
            "criterions": [
                {
                    "exact_snippets": "Discontinuation of all antibacterial antibiotics (except those used for Pneumocystis jiroveci prophylaxis) for 2 days",
                    "criterion": "antibacterial antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "antibiotics used for Pneumocystis jiroveci prophylaxis"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cord blood",
            "criterions": [
                {
                    "exact_snippets": "Cord blood",
                    "criterion": "cord blood",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Absolute neutrophil count (ANC) recovery to > 0.5 x 10^9/L from nadir, without ongoing growth factor support",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) recovery to > 0.5 x 10^9/L from nadir",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "recovery from nadir",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without ongoing growth factor support",
                    "criterion": "growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "ongoing support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to take oral medications",
            "criterions": [
                {
                    "exact_snippets": "Able to take oral medications",
                    "criterion": "ability to take oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned GVHD prophylaxis using one of the following regimens:",
            "criterions": [
                {
                    "exact_snippets": "Planned GVHD prophylaxis using one of the following regimens",
                    "criterion": "GVHD prophylaxis regimen",
                    "requirements": [
                        {
                            "requirement_type": "planned use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "regimen type",
                            "expected_value": "one of the following regimens"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ELIGIBILITY CRITERIA FOR RANDOMIZATION: No moderate to severe chronic GVHD",
            "criterions": [
                {
                    "exact_snippets": "No moderate to severe chronic GVHD",
                    "criterion": "chronic GVHD",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "none",
                                "mild"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ELIGIBILITY CRITERIA FOR RANDOMIZATION: Resolution of all acute toxicities (other than anemia and thrombocytopenia) to Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or lower",
            "criterions": [
                {
                    "exact_snippets": "Resolution of all acute toxicities (other than anemia and thrombocytopenia) to Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or lower",
                    "criterion": "acute toxicities (excluding anemia and thrombocytopenia)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Human leukocyte antigen (HLA)-matched sibling donor",
            "criterions": [
                {
                    "exact_snippets": "Human leukocyte antigen (HLA)-matched sibling donor",
                    "criterion": "donor",
                    "requirements": [
                        {
                            "requirement_type": "relationship",
                            "expected_value": "sibling"
                        },
                        {
                            "requirement_type": "HLA matching",
                            "expected_value": "matched"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed informed consent",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ELIGIBILITY CRITERIA FOR RANDOMIZATION: No concurrent antibiotics to treat infections. Prophylactic antiviral and antifungal antibiotics used to prevent infections are allowed",
            "criterions": [
                {
                    "exact_snippets": "No concurrent antibiotics to treat infections",
                    "criterion": "concurrent antibiotics to treat infections",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prophylactic antiviral and antifungal antibiotics used to prevent infections are allowed",
                    "criterion": "prophylactic antiviral and antifungal antibiotics used to prevent infections",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calcineurin inhibitor (tacrolimus or cyclosporine) plus methotrexate",
            "criterions": [
                {
                    "exact_snippets": "Calcineurin inhibitor (tacrolimus or cyclosporine)",
                    "criterion": "calcineurin inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": [
                                "tacrolimus",
                                "cyclosporine"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "plus methotrexate",
                    "criterion": "methotrexate use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Severe food allergy in the form of anaphylaxis or attributable symptoms requiring hospitalization",
            "criterions": [
                {
                    "exact_snippets": "Severe food allergy in the form of anaphylaxis",
                    "criterion": "severe food allergy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "anaphylaxis"
                        }
                    ]
                },
                {
                    "exact_snippets": "attributable symptoms requiring hospitalization",
                    "criterion": "food allergy symptoms",
                    "requirements": [
                        {
                            "requirement_type": "hospitalization_required",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving or planned to receive other experimental agents (including ex vivo T-cell depletion) to prevent GVHD. The use of other experimental agents is prohibited unless approved by the principal investigator (PI) of the other trial",
            "criterions": [
                {
                    "exact_snippets": "Receiving or planned to receive other experimental agents (including ex vivo T-cell depletion) to prevent GVHD.",
                    "criterion": "receipt of other experimental agents to prevent GVHD",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "The use of other experimental agents is prohibited unless approved by the principal investigator (PI) of the other trial",
                    "criterion": "approval by principal investigator of the other trial for use of experimental agents",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of chronic aspiration or conditions predisposing to aspiration (e.g. neuromuscular disorders)",
            "criterions": [
                {
                    "exact_snippets": "History of chronic aspiration",
                    "criterion": "chronic aspiration",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "conditions predisposing to aspiration (e.g. neuromuscular disorders)",
                    "criterion": "conditions predisposing to aspiration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}